103 related articles for article (PubMed ID: 21726161)
21. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of almotriptan in controlled clinical trials.
Mathew NT
Eur Neurol; 2005; 53 Suppl 1():29-33. PubMed ID: 15920335
[TBL] [Abstract][Full Text] [Related]
23. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study.
Leone M; Vila C; McGown C
Expert Rev Neurother; 2010 Sep; 10(9):1399-408. PubMed ID: 20819011
[TBL] [Abstract][Full Text] [Related]
24. [Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis].
Slof J; Láinez JM; Comas A; Heras J
Neurologia; 2009 Apr; 24(3):147-53. PubMed ID: 19418289
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study.
Massiou H; Pradalier A; Donnet A; Lanteri-Minet M; Allaf B
Eur Neurol; 2006; 55(4):198-203. PubMed ID: 16772716
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
Pascual J
Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
28. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
29. Treatment strategies for menstrually related migraine.
Allais G; Castagnoli Gabellari I; Mana O; Benedetto C
Womens Health (Lond); 2012 Sep; 8(5):529-41. PubMed ID: 22934727
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg.
Schreiber CP; Cady RK
Clin Ther; 2007; 29 Suppl():2511-9. PubMed ID: 18164918
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic evaluation of frovatriptan.
Negro A; Lionetto L; Casolla B; Lala N; Simmaco M; Martelletti P
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1449-58. PubMed ID: 21929465
[TBL] [Abstract][Full Text] [Related]
32. A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache.
Bakhshayesh B; Seyed Saadat SM; Rezania K; Hatamian H; Hossieninezhad M
Am J Emerg Med; 2013 Mar; 31(3):540-4. PubMed ID: 23380105
[TBL] [Abstract][Full Text] [Related]
33. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Elkind AH; MacGregor EA
Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529
[TBL] [Abstract][Full Text] [Related]
34. Is iron deficiency anemia related to menstrual migraine? Post hoc analysis of an observational study evaluating clinical characteristics of patients with menstrual migraine.
Vuković-Cvetković V; Plavec D; Lovrencić-Huzjan A; Galinović I; Serić V; Demarin V
Acta Clin Croat; 2010 Dec; 49(4):389-94. PubMed ID: 21830449
[TBL] [Abstract][Full Text] [Related]
35. Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary.
van Casteren DS; Verhagen IE; van der Arend BWH; van Zwet EW; MaassenVanDenBrink A; Terwindt GM
Neurology; 2021 Oct; 97(17):e1661-e1671. PubMed ID: 34493613
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres.
Granella F; Sances G; Allais G; Nappi RE; Tirelli A; Benedetto C; Brundu B; Facchinetti F; Nappi G
Cephalalgia; 2004 Sep; 24(9):707-16. PubMed ID: 15315526
[TBL] [Abstract][Full Text] [Related]
37. Almotriptan and zolmitriptan in the acute treatment of migraine.
Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlöf CG; Mateos V; Dowson AJ; Raets I; Cunha L; Färkkilä M; Manzoni GC
Acta Neurol Scand; 2007 Jan; 115(1):34-40. PubMed ID: 17156263
[TBL] [Abstract][Full Text] [Related]
38. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
39. Acute management of migraine.
Chowdhury D
J Assoc Physicians India; 2010 Apr; 58 Suppl():21-5. PubMed ID: 21049703
[TBL] [Abstract][Full Text] [Related]
40. Almotriptan: a review of 20 years' clinical experience.
Pascual J; Vila C
Expert Rev Neurother; 2019 Aug; 19(8):759-768. PubMed ID: 30845850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
